Figure 1.

Outcome following autologous stem cell transplant (ASCT) according to day 100 minimal residual disease (MRD) and induction therapy received. The impact of MRD on outcome did not differ according to induction therapy received. For MRD-negative patients the median PFS for CTD was 28.9 months versus 28.7 months for CVAD (P=0.54) (A) while the median OS was 80.6 months and not reached, respectively (P=0.81) (B). Similarly for MRD-positive patients, median PFS for CTD was 14.9 months versus 15.9 months for CVAD (P=0.96) (A) and median OS 58.7 months and 61.9 months, respectively (P=0.91) (B). A similar pattern is also seen when PFS analysis is restricted to complete response (CR) patients (C).